Extended Data Fig. 6: Validation of LDLR with a CCHFV patient isolate.
From: Crimean–Congo haemorrhagic fever virus uses LDLR to bind and enter host cells
CCHFV was isolated from the serum of a Turkish patient and this clinical isolate used for all subsequent experiment in Fig. 6. a, b, Levels of CCHFV infections of SW13 cells treated (MOI 0.01, 24hpi) with the indicated concentrations of sLDLR, and sVLDLR. a, sLDLR. b, sVLDLR c, Levels of infection with clinical CCHFV in wild type and LDLR KO (clones C2 and C12) Vero cells and in wild type and LDLR KO (clones C8, C10 and C11) A549 cells (MOI 0.1, 24hpi). Graphs show mean value ± SD. n = 3 independent experiments. P values were calculating using One-way ANOVA. *P < 0.05, **P < 0.01; *** P < 0.001; **** P < 0.0001. Non significant: p > 0.05. Exact p-values are available in Source data.
